Fairmount Partners – Spring News

Fairmount Partners is an independent investment banking firm focused on serving the needs of middle market and emerging growth companies. We provide a complete range of investment banking and capital advisory services for our clients including merger and acquisition advisory, financing advisory, fairness opinions and valuations and strategic corporate development advisory services.

Spring 2014 News

  • Fairmount Partners Represented Medpace, Inc., a leading pharmaceutical contract research organization (CRO), in their sale to an entity funded by European private equity firm, Cinven and Medpace management, for a total consideration of US $915 million plus certain cash inflows relating to the period of ownership. Fairmount also represented Medpace in its 2011 sale to global private equity firm CCMP Capital Advisors, and completed two other transactions with Medpace. Medpace is a global CRO business providing management services to the R&D departments of pharma, biotech and medical device clients to help plan and oversee their clinical trials.

 

  • Fairmount served as the exclusive financial advisor to the management team / owners of the national revenue cycle consulting firm, MultiCare Consulting Services, LLC (MCS) in the sale of the assets of the MCS consulting business. This sale was executed through a management buyout arrangement involving former MCS Managing Directors, James McHugh, Tim Kinney and Jake Morris.¬†¬†Under the terms of the sale, the assets of the MCS business were acquired by a newly formed independent consulting business, McKinnis Consulting Services, LLC, owned by McHugh, Kinney and Morris. The new entity is headquartered in Chicago, IL, with the former MCS employees joining the newly formed, McKinnis Consulting Services. MCS was founded in 2009 and provides a full suite of revenue cycle consulting services.

 

  • Fairmount represented Choice Pharma, a Pan-Asian contract research organization, in their successful sale to Clinipace Worldwide, a CRO based in North Carolina. Choice Pharma is one of the leading Asian CROs, with offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia. Terms of the transaction were not disclosed. Together, Choice Pharma and Clinipace Worldwide will have a staff of over 640, and the combined company has managed over 1,500 clinical research studies and 300+ completed regulatory and strategic development engagements.

©2017 PACT All Rights Reserved